AAV1-hOTOF基因治疗常染色体隐性耳聋9:单臂试验
这项单臂、单中心试验纳入6例OTOF双等位基因突变所致重度至完全性听力损失的儿童,经圆窗向耳蜗单次注射AAV1-hOTOF。6周内未发生剂量限制性毒性或严重不良事件,5例听力恢复,听性脑干反应平均阈值降低40-57 dB,有听力恢复者言语感知改善。
要点
- AAV1-hOTOF耳蜗内单次注射在OTOF突变耳聋儿童中未观察到剂量限制性毒性或严重不良事件。
- 6例中5例听力恢复,平均ABR阈值降低40-57 dB(0.5-4.0 kHz)。
- 有听力恢复的参与者言语感知改善。
核心结论
- AAV1-hOTOF基因治疗作为常染色体隐性耳聋9儿童的新型治疗是安全且有效的。
研究设计与样本
- 单臂、单中心试验,纳入年龄1-18岁、OTOF双等位基因突变确诊、重度至完全性听力损失且无双侧人工耳蜗的儿童。
- 通过圆窗向耳蜗单次注射AAV1-hOTOF,主要终点为注射后6周的剂量限制性毒性,所有分析按意向性治疗原则进行。
- 2022年10月19日至2023年6月9日筛查425名参与者,最终入组6名儿童接受AAV1-hOTOF基因治疗。
主要发现
- 6例中1例接受9×10^11 vg剂量,5例接受1.5×10^12 vg剂量;所有参与者完成至第26周的随访。
- 未发生剂量限制性毒性或严重不良事件;共观察48例不良事件,其中46例(96%)为1-2级,2例(4%)为3级(1例参与者中性粒细胞计数降低)。
- 5例儿童听力恢复,表现为0.5-4.0 kHz平均听性脑干反应(ABR)阈值降低40-57 dB。
- 接受9×10^11 vg剂量的参与者平均ABR阈值从基线大于95 dB改善至第4周68 dB、第13周53 dB、第26周45 dB。
- 接受1.5×10^12 vg剂量且有听力恢复的4例儿童,第26周平均ABR阈值从基线大于95 dB分别变为48 dB、38 dB、40 dB和55 dB;有听力恢复的参与者言语感知改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autosomal recessive deafness 9, caused by mutations of the OTOF gene, is characterised by congenital or prelingual, severe-to-complete, bilateral hearing loss. However, no pharmacological treatment is currently available for congenital deafness. In this Article, we report the safety and efficacy of gene therapy with an adeno-associated virus (AAV) serotype 1 carrying a human OTOF transgene (AAV1-hOTOF) as a treatment for children with autosomal recessive deafness 9. METHODS: This single-arm, single-centre trial enrolled children (aged 1-18 years) with severe-to-complete hearing loss and confirmed mutations in both alleles of OTOF, and without bilateral cochlear implants. A single injection of AAV1-hOTOF was administered into the cochlea through the round window. The primary endpoint was dose-limiting toxicity at 6 weeks after injection. Auditory function and speech were assessed by appropriate auditory perception evaluation tools. All analyses were done according to the intention-to-treat principle. This trial is registered with Chinese Clinical Trial Registry, ChiCTR2200063181, and is ongoing. FINDINGS: Between Oct 19, 2022, and June 9, 2023, we screened 425 participants for eligibility and enrolled six children for AAV1-hOTOF gene therapy (one received a dose of 9 × 1011 vector genomes [vg] and five received 1·5 × 1012 vg). All participants completed follow-up visits up to week 26. No dose-limiting toxicity or serious adverse events occurred. In total, 48 adverse events were observed; 46 (96%) were grade 1-2 and two (4%) were grade 3 (decreased neutrophil count in one participant). Five children had hearing recovery, shown by a 40-57 dB reduction in the average auditory brainstem response (ABR) thresholds at 0·5-4·0 kHz. In the participant who received the 9 × 1011 vg dose, the average ABR threshold was improved from greater than 95 dB at baseline to 68 dB at 4 weeks, 53 dB at 13 weeks, and 45 dB at 26 weeks. In those who received 1·5 × 1012 AAV1-hOTOF, the average ABR thresholds changed from greater than 95 dB at baseline to 48 dB, 38 dB, 40 dB, and 55 dB in four children with hearing recovery at 26 weeks. Speech perception was improved in participants who had hearing recovery. INTERPRETATION: AAV1-hOTOF gene therapy is safe and efficacious as a novel treatment for children with autosomal recessive deafness 9. FUNDING: National Natural Science Foundation of China, National Key R&D Program of China, Science and Technology Commission of Shanghai Municipality, and Shanghai Refreshgene Therapeutics.
引用
- Lv J, Wang H, Cheng X, et al. AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial. Lancet. 2024. PMID: 38280389. doi:10.1016/S0140-6736(23)02874-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。